Phase II Trial of Gefitinib in Recurrent Glioblastoma

摘要: Purpose To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Patients Methods This was an open-label, single-center phase II trial. Fifty-seven first recurrence glioblastoma who were previously treated surgical resection, radiation, usually chemotherapy underwent open biopsy or resection at evaluation for confirmation tumor recurrence. Each patient initially received 500 mg orally once daily; dose escalation to 750 then 1,000 mg, if enzyme-inducing antiepileptic drugs dexamethasone, allowed within each patient. Results Although no objective responses seen among 53 assessable patients, only 21% (11 patients) had measurable disease treatment initiation. Seventeen percent (nine least six 4-week cycl...